{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T01:00:46Z","timestamp":1770512446669,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T00:00:00Z","timestamp":1594339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T00:00:00Z","timestamp":1594339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003554","name":"Lundbeckfonden","doi-asserted-by":"publisher","award":["R219-2016-270"],"award-info":[{"award-number":["R219-2016-270"]}],"id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s40264-020-00969-6","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T09:03:43Z","timestamp":1594371823000},"page":"1035-1044","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Use of Pregabalin and Worsening Heart Failure: A Nationwide Cohort Study"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7417-8889","authenticated-orcid":false,"given":"Marie","family":"Lund","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gry","family":"Poulsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn","family":"Pasternak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niklas","family":"Worm Andersson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mads","family":"Melbye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Svanstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,10]]},"reference":[{"key":"969_CR1","unstructured":"European Medicines Agency. Summary of Product Characteristics: Lyrica (version last updated 7\/12\/2018)."},{"key":"969_CR2","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1001\/jama.2018.12358","volume":"320","author":"F Montastruc","year":"2018","unstructured":"Montastruc F, Loo SY, Renoux C. Trends in first gabapentin and pregabalin prescriptions in primary care in the United Kingdom, 1993\u20132017. JAMA. 2018;320:2149\u201351.","journal-title":"JAMA"},{"key":"969_CR3","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1001\/jamainternmed.2017.7856","volume":"178","author":"ME Johansen","year":"2018","unstructured":"Johansen ME. Gabapentinoid use in the United States 2002 through 2015. JAMA Intern Med. 2018;178:292\u20134.","journal-title":"JAMA Intern Med."},{"key":"969_CR4","first-page":"3","volume":"7","author":"HL Larsen","year":"2018","unstructured":"Larsen HL. Misbrug af gabapentin og pregabalin\u2014forsigtighed ved behandling af personer med opioidmisbrug. Rationel Farmakoterapi. 2018;7:3\u00ad\u20134.","journal-title":"Rationel Farmakoterapi"},{"key":"969_CR5","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s00228-012-1213-x","volume":"68","author":"G Zaccara","year":"2012","unstructured":"Zaccara G, Perucca P, Gangemi PF. The adverse event profile of pregabalin across different disorders: a meta-analysis. Eur J Clin Pharmacol. 2012;68:903\u201312.","journal-title":"Eur J Clin Pharmacol"},{"key":"969_CR6","doi-asserted-by":"publisher","first-page":"e023600","DOI":"10.1136\/bmjopen-2018-023600","volume":"9","author":"IJ Onakpoya","year":"2019","unstructured":"Onakpoya IJ, Thomas ET, Lee JJ, Goldacre B, Heneghan CJ. Benefits and harms of pregabalin in the management of neuropathic pain: a rapid review and meta-analysis of randomised clinical trials. BMJ Open. 2019;9:e023600.","journal-title":"BMJ Open"},{"key":"969_CR7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ccl.2013.09.002","volume":"32","author":"G Sayer","year":"2014","unstructured":"Sayer G, Bhat G. The renin\u2013angiotensin\u2013aldosterone system and heart failure. Cardiol Clin. 2014;32:21\u201332.","journal-title":"Cardiol Clin"},{"key":"969_CR8","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.cardfail.2006.11.006","volume":"13","author":"N Murphy","year":"2007","unstructured":"Murphy N, Mockler M, Ryder M, Ledwidge M, McDonald K. Decompensation of chronic heart failure associated with pregabalin in patients with neuropathic pain. J Card Fail. 2007;13:227\u20139.","journal-title":"J Card Fail."},{"key":"969_CR9","doi-asserted-by":"publisher","first-page":"922","DOI":"10.2459\/JCM.0b013e3282fb7629","volume":"9","author":"RL Page","year":"2008","unstructured":"Page RL, Cantu M, Lindenfeld J, Hergott LJ, Lowes BD. Possible heart failure exacerbation associated with pregabalin: case discussion and literature review. J Cardiovasc Med (Hagerstown). 2008;9:922\u20135.","journal-title":"J Cardiovasc Med (Hagerstown)."},{"key":"969_CR10","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/j.1365-2125.2008.03196.x","volume":"66","author":"RHE De Smedt","year":"2008","unstructured":"De Smedt RHE, Jaarsma T, van den Broek SAJ, Haaijer-Ruskamp FM. Decompensation of chronic heart failure associated with pregabalin in a 73-year-old patient with postherpetic neuralgia: a case report. Br J Clin Pharmacol. 2008;66:327\u20138.","journal-title":"Br J Clin Pharmacol"},{"key":"969_CR11","unstructured":"US FDA. Lyrica: full prescribing information, NDA 021446 (version updated 23 Mar 2019)."},{"key":"969_CR12","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","volume":"62","author":"CW Yancy","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF\/AHA guideline for the management of heart failure. J Am Coll Cardiol. 2013;62:e147\u2013239.","journal-title":"J Am Coll Cardiol"},{"key":"969_CR13","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1002\/pds.4239","volume":"26","author":"JM-W Ho","year":"2017","unstructured":"Ho JM-W, McDonald EM, Luo J, Gomes T, Antoniou T, Mamdani MM, et al. Pregabalin and heart failure: a population-based study. Pharmacoepidemiol Drug Saf. 2017;26:1087\u201392.","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"969_CR14","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/ijcp.12182","volume":"68","author":"B Wettermark","year":"2014","unstructured":"Wettermark B, Brandt L, Kieler H, Bod\u00e9n R. Pregabalin is increasingly prescribed for neuropathic pain, generalised anxiety disorder and epilepsy but many patients discontinue treatment. Int J Clin Pract. 2014;68:104\u201310.","journal-title":"Int J Clin Pract"},{"key":"969_CR15","unstructured":"Danish Medicines Agency (L\u00e6gemiddelstyrelsen). Summary of Product Characteristics: Gabapentin \u201cAbZ\u201d, hard capsules (version last updated 29 Jun 2018)."},{"key":"969_CR16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1177\/1403494810394717","volume":"39","author":"HW Kildemoes","year":"2011","unstructured":"Kildemoes HW, Sorensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health. 2011;39:38\u201341.","journal-title":"Scand J Public Health."},{"key":"969_CR17","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1177\/1403494811401482","volume":"39","author":"E Lynge","year":"2011","unstructured":"Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health. 2011;39:30\u20133.","journal-title":"Scand J Public Health."},{"key":"969_CR18","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/papr.12146","volume":"15","author":"R Freynhagen","year":"2015","unstructured":"Freynhagen R, Serpell M, Emir B, Whalen E, Parsons B, Clair A, et al. A comprehensive drug safety evaluation of pregabalin in peripheral neuropathic pain. Pain Pract. 2015;15:47\u201357.","journal-title":"Pain Pract."},{"key":"969_CR19","doi-asserted-by":"publisher","first-page":"e012832","DOI":"10.1136\/bmjopen-2016-012832","volume":"6","author":"J Sundb\u00f8ll","year":"2016","unstructured":"Sundb\u00f8ll J, Adelborg K, Munch T, Fr\u00f8slev T, S\u00f8rensen HT, B\u00f8tker HE, et al. Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry: a validation study. BMJ Open. 2016;6:e012832.","journal-title":"BMJ Open"},{"key":"969_CR20","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2147\/CLEP.S12457","volume":"2","author":"S Nielsen","year":"2010","unstructured":"Nielsen S, Nielsen FE. Positive predictive value and impact of misdiagnosis of a heart failure diagnosis in administrative registers among patients admitted to a University Hospital cardiac care unit. Clin Epidemiol. 2010;2:235.","journal-title":"Clin Epidemiol"},{"key":"969_CR21","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1093\/aje\/kwj149","volume":"163","author":"MA Brookhart","year":"2006","unstructured":"Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, St\u00fcrmer T. Variable selection for propensity score models. Am J Epidemiol. 2006;163:1149\u201356.","journal-title":"Am J Epidemiol"},{"key":"969_CR22","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/sim.5984","volume":"33","author":"PC Austin","year":"2014","unstructured":"Austin PC. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med. 2014;33:1242\u201358.","journal-title":"Stat Med"},{"key":"969_CR23","unstructured":"European Medicines Agency. EPAR\u2014procedural steps taken and scientific information after the authorisation Lyrica (version updated 7\/12\/2018)."},{"key":"969_CR24","unstructured":"Danish Medicines Agency (L\u00e6gemiddelstyrelsen). Summary of Product Characteristics: Duloxetin \u201c2care4\u201d (version last updated 2 Dec 2019)."},{"key":"969_CR25","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jpsychires.2020.02.022","volume":"124","author":"K Park","year":"2020","unstructured":"Park K, Kim S, Ko Y-J, Park B-J. Duloxetine and cardiovascular adverse events: a systematic review and meta-analysis. J Psychiatr Res. 2020;124:109\u201314.","journal-title":"J Psychiatr Res"},{"key":"969_CR26","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1007\/s40264-018-0695-6","volume":"41","author":"LO de Landaluce","year":"2018","unstructured":"de Landaluce LO, Carbonell P, Asensio C, Escoda N, L\u00f3pez P, Laporte JR. Gabapentin and pregabalin and risk of atrial fibrillation in the elderly: a population-based cohort study in an electronic prescription database. Drug Saf. 2018;41:1325\u201331.","journal-title":"Drug Saf."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-020-00969-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-020-00969-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-020-00969-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T23:17:26Z","timestamp":1625872646000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-020-00969-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,10]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["969"],"URL":"https:\/\/doi.org\/10.1007\/s40264-020-00969-6","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,10]]},"assertion":[{"value":"10 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Lundbeck Foundation (R219-2016-270). Dr Pasternak was supported by an investigator grant from the Strategic Research Area Epidemiology program at Karolinska Institutet.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Marie Lund reports personal fees from Dansk L\u00e6gemiddel Information A\/S, outside the submitted work. Henrik Svanstr\u00f6m is an employee of IQVIA and has received consulting fees from Celgene, outside the submitted work. Gry Poulsen, Bj\u00f6rn Pasternak, Niklas Worm Andersson and Mads Melbye declare they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Danish Data Protection Agency. Approval by an Ethics Committee is not needed for register-based research in Denmark.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The data underlying the presented results in this paper can be shared by sending a request via the regular mechanism for obtaining access to data from the Danish National Registers ().","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Computer codes for the statistical analyses are available on request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}